Bhatt Elizabeth 4
4 · eFFECTOR Therapeutics, Inc. · Filed Aug 27, 2021
Insider Transaction Report
Form 4
Bhatt Elizabeth
Director
Transactions
- Conversion
Class A Common Stock
2021-08-25+9,047→ 9,047 total(indirect: By LLC) - Disposition to Issuer
Class B Common Stock
2021-08-25−8,453→ 8,453 total(indirect: By LLC)→ Common Stock (8,453 underlying) - Conversion
Class B Common Stock
2021-08-25−9,047→ 0 total(indirect: By LLC)→ Common Stock (9,047 underlying)
Footnotes (3)
- [F1]On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock.
- [F2]Represents shares held directly by the Sponsor, of which LWAC D&O LLC is a member.
- [F3]Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.